Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses. METHODS: From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) enco...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 438.2KB)
- Publisher copy:
- Local pid:
- Deposit date:
- Copyright holder:
- O’Hara et al
- Copyright date:
- Copyright © 2012 O’Hara et al. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: email@example.com. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
If you are the owner of this record, you can report an update to it here: Report update to this record